Chemomab Therapeutics Ltd.

Greetings and welcome to the ChemoMab first quarter 2022 earnings call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I'd now like to turn the conference over to your host, Barbara Lindheim, Consulting Vice President Strategic Communications for ChemoMab. Thank you. You may begin.

Welcome to the ChemoMap Therapeutics 2022 First Quarter Conference Call. Thank you for attending. I am Barbara Lindheim, Consulting Vice President of Strategic Communications at ChemoMap. With me today are Dale Post, our Chairman and CEO, Don Marvin, CFO, Chief Operating Officer, and Executive Vice President, Dr. David Wiener, Interim CMO, and Dr. Adi Moore, our co-founder and chief scientific officer. Before turning the call over to Dale, please take note of our forward-looking statement. Today's call may contain forward-looking statements, which may be identified by words such as may, could, will, expect, intend, plan, and other similar words and expressions. All forward-looking statements made today are based on management's current expectations, assumptions, and beliefs about our business and the environment in which we operate. These statements are subject to risks and uncertainties that could cause our actual results to materially differ from those expressed or implied on today's call. Listeners should not place undue reliance on forward-looking statements. and are encouraged to review our earnings press release that we issued this morning together with our SEC filings for a more complete discussion of factors that could cause our actual results to differ materially from those expressed or applied in forward-looking statements. You can read a comprehensive list of those factors under the heading Risk Factors contained in our annual report on Form 10-K together with factors under similar headings and the other reports and materials we file with the SEC. Except as required by federal securities laws, QMMAB does not undertake to publicly update or revise any forward-looking statements subsequent to the date made as a result of new information, future events, changing circumstances, or for any other reason. Let me now turn the call over to Dale.

Welcome to the QMMAB conference call covering the first quarter of 2022. It's just been two months since our last conference call, and I'm pleased to report that we have been making good progress in refining and implementing the revisions to the CM101 clinical program that we outlined in March. CM101 is a first-in-class monoclonal antibody that neutralizes CCL24, a soluble protein implicated in both fibrosis and inflammation. We are currently developing CM101 for the rare disease indications of primary sclerosing cholangitis, or PSC, and systemic sclerosis, or SSC, as well as evaluating other potential clinical indications where its multiple mechanisms of action at the confluence of fibrosis and inflammation could be valuable. Our interim CMO, David Wiener, will have more to say on our clinical progress shortly. There are several areas of notable developments in the first quarter. We named Jack Lawler, Vice President of Global Clinical Development Operations, Jack, who is based in the US, is a tremendous addition to our clinical team, bringing us more than 20 years of diverse clinical drug development experience. Jack's deep knowledge of clinical trial operations is already proving invaluable, working with both our existing clinical trial staff in Israel and with additional essential team members he is bringing on board, including in the United States. Jack will be playing a pivotal role in advancing our clinical development objectives, and we are delighted to have someone with his expertise and hands-on knowledge in this important position. During the quarter, we presented data at two scientific meetings. At the International Rheumatology Conference in Israel, our CSO, Dr. Adi Mohr, presented preclinical data on CM101 as a possible treatment for systemic sclerosis with the potential to impact inflammation, fibrosis, and endothelial damage. Data from patient samples demonstrated that the soluble protein, PCL24, the target of CM-101, is highly expressed in samples from systemic sclerosis patients compared to healthy individuals. CCL24 levels also correlated with fibrotic markers and disease progression. And in a well-established experimental systemic sclerosis model, CM-101 profoundly reduced skin and lung fibrosis. Our scientific collaborator, Professor Francesco Delgado, a respected scleroderma key opinion leader at the University of Leeds, presented CM1-101 data at the 7th Annual Systemic Sclerosis World Congress. The data supports the role of CCL24 as a novel biological target for systemic sclerosis, demonstrating that systemic sclerosis patients have elevated serum levels of CCL24. Furthermore, high CCL24 serum levels were correlated with disease activity and worse prognosis in these patients as reflected by high fibrotic activity and deterioration of lung function over time. This provides additional evidence that CM-101 is addressing an important biological target in systemic sclerosis. These data contribute to our optimism that CM-101 could be a valuable new therapy for the treatment of systemic sclerosis, a progressive and lethal disease that currently lacks effective therapies. During the quarter, we also participated in the annual Oppenheimer Healthcare Conference and the Cantor Fitzgerald Rare Orphan Disease Summit. Now, let me turn it over to Dr. David Weiner, who is leading our clinical team as we focus on advancing our clinical development program for CM101. Recall that our aims in the program are to optimize the overall clinical development plan for CM101 by, first, decreasing overall development risk and, second, maximizing the clinical data obtained to facilitate clinical decision making and support advancement to registration trials. David?